{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:33:32Z","timestamp":1791232412688,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00277-024-06023-0","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:02:10Z","timestamp":1727395330000},"page":"4545-4556","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as novel prognostic biomarkers in BCR-ABL negative myeloproliferative neoplasms"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0907-7552","authenticated-orcid":false,"given":"Mirjana","family":"Cvetkovi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidora","family":"Arsenovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihailo","family":"Smiljani\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Sobas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrija","family":"Bogdanovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danijela","family":"Lekovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"6023_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ijlh.14086","volume":"45","author":"ZY Ng","year":"2023","unstructured":"Ng ZY, Fuller KA, Mazza-Parton A, Erber WN (2023) Morphology of myeloproliferative neoplasms. Int J Lab Hematol 45:59\u201370. https:\/\/doi.org\/10.1111\/ijlh.14086","journal-title":"Int J Lab Hematol"},{"key":"6023_CR2","unstructured":"Hematopoietic and lymphoid neoplasm database (2024) SEER n.d. https:\/\/seer.cancer.gov\/seertools\/hemelymph\/ Accessed July 19"},{"issue":"7","key":"6023_CR3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and Histiocytic\/Dendritic neoplasms. Leukemia 36(7):1703\u20131719. https:\/\/doi.org\/10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"issue":"11","key":"6023_CR4","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM et al (2022) International Consensus classification of myeloid neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11):1200\u20131228. https:\/\/doi.org\/10.1182\/blood.2022015850","journal-title":"Blood"},{"issue":"1","key":"6023_CR5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/ajh.26751","volume":"98","author":"J Thiele","year":"2023","unstructured":"Thiele J, Kvasnicka HM, Orazi A, Gianelli U, Gangat N, Vannucchi AM et al (2023) The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms. Am J Hematol 98(1):166\u2013179. https:\/\/doi.org\/10.1002\/ajh.26751","journal-title":"Am J Hematol"},{"issue":"4","key":"6023_CR6","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1182\/blood.2021014668","volume":"141","author":"JM O\u2019Sullivan","year":"2023","unstructured":"O\u2019Sullivan JM, Mead AJ, Psaila B (2023) Single-cell methods in myeloproliferative neoplasms: old questions, new technologies. Blood 141(4):380\u2013390. https:\/\/doi.org\/10.1182\/blood.2021014668","journal-title":"Blood"},{"issue":"1","key":"6023_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13045-021-01116-z","volume":"14","author":"G Greenfield","year":"2021","unstructured":"Greenfield G, McMullin MF, Mills K (2021) Molecular pathogenesis of the myeloproliferative neoplasms. J Hematol Oncol 14(1):103. https:\/\/doi.org\/10.1186\/s13045-021-01116-z","journal-title":"J Hematol Oncol"},{"issue":"3","key":"6023_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11899-019-00508-w","volume":"14","author":"LF Mendez Luque","year":"2019","unstructured":"Mendez Luque LF, Blackmon AL, Ramanathan G, Fleischman AG (2019) Key role of inflammation in Myeloproliferative neoplasms: Instigator of Disease initiation, progression. And symptoms. Curr Hematol Malig Rep 14(3):145\u2013153. https:\/\/doi.org\/10.1007\/s11899-019-00508-w","journal-title":"Curr Hematol Malig Rep"},{"issue":"7","key":"6023_CR9","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.3390\/cancers12071810","volume":"12","author":"MF McMullin","year":"2020","unstructured":"McMullin MF, Anderson LA (2020) Aetiology of Myeloproliferative Neoplasms. Cancers (Basel) 12(7):1810. https:\/\/doi.org\/10.3390\/cancers12071810","journal-title":"Cancers (Basel)"},{"issue":"4","key":"6023_CR10","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s11899-014-0228-z","volume":"9","author":"LA Anderson","year":"2014","unstructured":"Anderson LA, McMullin MF (2014) Epidemiology of MPN: what do we know? Curr Hematol Malig Rep 9(4):340\u2013349. https:\/\/doi.org\/10.1007\/s11899-014-0228-z","journal-title":"Curr Hematol Malig Rep"},{"issue":"2","key":"6023_CR11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.hoc.2020.12.001","volume":"35","author":"D Tremblay","year":"2021","unstructured":"Tremblay D, Yacoub A, Hoffman R (2021) Overview of myeloproliferative neoplasms: history, Pathogenesis, Diagnostic Criteria, and complications. Hematol Oncol Clin North Am 35(2):159\u2013176. https:\/\/doi.org\/10.1016\/j.hoc.2020.12.001","journal-title":"Hematol Oncol Clin North Am"},{"key":"6023_CR12","doi-asserted-by":"publisher","unstructured":"Hasselbalch HC (2012) Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 119(14):3219-25. https:\/\/doi.org\/10.1182\/blood-2011-11-394775","DOI":"10.1182\/blood-2011-11-394775"},{"issue":"5","key":"6023_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.7326\/m17-0028","volume":"168","author":"M Hultcrantz","year":"2018","unstructured":"Hultcrantz M, Bj\u00f6rkholm M, Dickman PW, Landgren O, Derolf \u00c5R, Kristinsson SY, Andersson TML (2018) Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a Population-based Cohort Study. Ann Intern Med 168(5):317\u2013325. https:\/\/doi.org\/10.7326\/m17-0028","journal-title":"Ann Intern Med"},{"issue":"100081","key":"6023_CR14","doi-asserted-by":"publisher","first-page":"100081","DOI":"10.1016\/j.tru.2021.100081","volume":"5","author":"S Kelliher","year":"2021","unstructured":"Kelliher S, Falanga A (2021) Thrombosis in myeloproliferative neoplasms: a clinical and pathophysiological perspective. Thromb Update 5(100081):100081. https:\/\/doi.org\/10.1016\/j.tru.2021.100081","journal-title":"Thromb Update"},{"issue":"4","key":"6023_CR15","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","volume":"115","author":"T Barbui","year":"2010","unstructured":"Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E et al (2010) Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 115(4):778\u2013782. https:\/\/doi.org\/10.1182\/blood-2009-08-238956","journal-title":"Blood"},{"issue":"1","key":"6023_CR16","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12885-019-5387-9","volume":"19","author":"T Rungjirajittranon","year":"2019","unstructured":"Rungjirajittranon T, Owattanapanich W, Ungprasert P, Siritanaratkul N, Ruchutrakool T (2019) A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms. BMC Cancer 19(1):184. https:\/\/doi.org\/10.1186\/s12885-019-5387-9","journal-title":"BMC Cancer"},{"issue":"1","key":"6023_CR17","doi-asserted-by":"publisher","first-page":"e12657","DOI":"10.1002\/rth2.12657","volume":"6","author":"T Barbui","year":"2022","unstructured":"Barbui T, Carobbio A, De Stefano V (2022) Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment. Res Pract Thromb Haemost 6(1):e12657. https:\/\/doi.org\/10.1002\/rth2.12657","journal-title":"Res Pract Thromb Haemost"},{"issue":"10","key":"6023_CR18","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C et al (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23(10):2224\u20132232. https:\/\/doi.org\/10.1200\/JCO.2005.07.062","journal-title":"J Clin Oncol"},{"issue":"5","key":"6023_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.patbio.2004.02.007","volume":"52","author":"G Finazzi","year":"2004","unstructured":"Finazzi G, low-dose aspirin in polycythemia (ECLAP) (2004) A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). Pathol Biol (Paris) 52(5):285\u2013288. https:\/\/doi.org\/10.1016\/j.patbio.2004.02.007","journal-title":"Pathol Biol (Paris)"},{"issue":"1","key":"6023_CR20","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41598-020-79431-7","volume":"11","author":"M Song","year":"2021","unstructured":"Song M, Graubard BI, Rabkin CS, Engels EA (2021) Neutrophil-to-lymphocyte ratio and mortality in the United States general population. Sci Rep 11(1):464. https:\/\/doi.org\/10.1038\/s41598-020-79431-7","journal-title":"Sci Rep"},{"issue":"1","key":"6023_CR21","doi-asserted-by":"publisher","first-page":"e23010","DOI":"10.1002\/jcla.23010","volume":"34","author":"R Farah","year":"2020","unstructured":"Farah R, Nseir W, Kagansky D, Khamisy-Farah R (2020) The role of neutrophil-lymphocyte ratio, and mean platelet volume in detecting patients with acute venous thromboembolism. J Clin Lab Anal 34(1):e23010. https:\/\/doi.org\/10.1002\/jcla.23010","journal-title":"J Clin Lab Anal"},{"issue":"7","key":"6023_CR22","doi-asserted-by":"publisher","first-page":"474","DOI":"10.4149\/bll_2021_078","volume":"122","author":"R Zahorec","year":"2021","unstructured":"Zahorec R (2021) Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl Lek Listy 122(7):474\u2013488. https:\/\/doi.org\/10.4149\/bll_2021_078","journal-title":"Bratisl Lek Listy"},{"issue":"7","key":"6023_CR23","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1158\/1055-9965.EPI-14-0146","volume":"23","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T et al (2014) Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 23(7):1204\u20131212. https:\/\/doi.org\/10.1158\/1055-9965.EPI-14-0146","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"6023_CR24","doi-asserted-by":"publisher","first-page":"e101119","DOI":"10.1371\/journal.pone.0101119","volume":"9","author":"X Zhou","year":"2014","unstructured":"Zhou X, Du Y, Huang Z, Xu J, Qiu T, Wang J et al (2014) Prognostic value of PLR in various cancers: a meta-analysis. PLoS ONE 9(6):e101119. https:\/\/doi.org\/10.1371\/journal.pone.0101119","journal-title":"PLoS ONE"},{"key":"6023_CR25","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3389\/fonc.2020.00841","volume":"10","author":"H Wang","year":"2020","unstructured":"Wang H, Ding Y, Li N, Wu L, Gao Y, Xiao C et al (2020) Prognostic value of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in Stage IV Advanced Gastric Cancer. Front Oncol 10:841. https:\/\/doi.org\/10.3389\/fonc.2020.00841","journal-title":"Front Oncol"},{"issue":"20","key":"6023_CR26","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"issue":"2","key":"6023_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","volume":"8","author":"T Barbui","year":"2018","unstructured":"Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P et al (2018) The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J 8(2):15. https:\/\/doi.org\/10.1038\/s41408-018-0054-y","journal-title":"Blood Cancer J"},{"issue":"8","key":"6023_CR28","first-page":"1128","volume":"90","author":"J Thiele","year":"2005","unstructured":"Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A (2005) European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90(8):1128\u20131132","journal-title":"Haematologica"},{"issue":"26","key":"6023_CR29","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E et al (2012) Development and validation of an International Prognostic score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 120(26):5128\u20135133 quiz 5252. https:\/\/doi.org\/10.1182\/blood-2012-07-444067","journal-title":"Blood"},{"issue":"13","key":"6023_CR30","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895\u20132901. https:\/\/doi.org\/10.1182\/blood-2008-07-170449","journal-title":"Blood"},{"issue":"9464","key":"6023_CR31","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464):1054\u20131061. https:\/\/doi.org\/10.1016\/S0140-6736(05)71142-9","journal-title":"Lancet"},{"issue":"1","key":"6023_CR32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.2353\/jmoldx.2010.090068","volume":"12","author":"JD Merker","year":"2010","unstructured":"Merker JD, Jones CD, Oh ST, Schrijver I, Gotlib J, Zehnder JL (2010) Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory. J Mol Diagn 12(1):58\u201364. https:\/\/doi.org\/10.2353\/jmoldx.2010.090068","journal-title":"J Mol Diagn"},{"issue":"5","key":"6023_CR33","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"issue":"1","key":"6023_CR34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3109\/10428194.2015.1045897","volume":"57","author":"BE Beltran","year":"2016","unstructured":"Beltran BE, Aguilar C, Qui\u00f1ones P, Morales D, Chavez JC, Sotomayor EM, Castillo JJ (2016) The neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leuk Lymphoma 57(1):58\u201362. https:\/\/doi.org\/10.3109\/10428194.2015.1045897","journal-title":"Leuk Lymphoma"},{"key":"6023_CR35","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.2147\/CMAR.S245928","volume":"12","author":"P Stefaniuk","year":"2020","unstructured":"Stefaniuk P, Szymczyk A, Podhorecka M (2020) The neutrophil to lymphocyte and lymphocyte to Monocyte Ratios as New Prognostic factors in hematological malignancies - A Narrative Review. Cancer Manag Res 12:2961\u20132977. https:\/\/doi.org\/10.2147\/CMAR.S245928","journal-title":"Cancer Manag Res"},{"issue":"1","key":"6023_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12959-022-00381-3","volume":"20","author":"V Otasevic","year":"2022","unstructured":"Otasevic V, Mihaljevic B, Milic N, Stanisavljevic D, Vukovic V, Tomic K et al (2022) Immune activation and inflammatory biomarkers as predictors of venous thromboembolism in lymphoma patients. Thromb J 20(1):20. https:\/\/doi.org\/10.1186\/s12959-022-00381-3","journal-title":"Thromb J"},{"key":"6023_CR37","doi-asserted-by":"publisher","first-page":"107602962311873","DOI":"10.1177\/10760296231187392","volume":"29","author":"C Hu","year":"2023","unstructured":"Hu C, Zhao B, Ye Q, Zou J, Li X, Wu H (2023) The diagnostic value of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for deep venous thrombosis: a systematic review and Meta-analysis. Clin Appl Thromb Hemost 29:10760296231187392. https:\/\/doi.org\/10.1177\/10760296231187392","journal-title":"Clin Appl Thromb Hemost"},{"issue":"5","key":"6023_CR38","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1177\/1076029617733039","volume":"24","author":"A Artoni","year":"2018","unstructured":"Artoni A, Abbattista M, Bucciarelli P, Gianniello F, Scalambrino E, Pappalardo E et al (2018) Platelet to lymphocyte ratio and neutrophil to lymphocyte ratio as risk factors for venous thrombosis. Clin Appl Thromb Hemost 24(5):808\u2013814. https:\/\/doi.org\/10.1177\/1076029617733039","journal-title":"Clin Appl Thromb Hemost"},{"issue":"5","key":"6023_CR39","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.21873\/anticanres.12579","volume":"38","author":"M Lucijanic","year":"2018","unstructured":"Lucijanic M, Cicic D, Stoos-Veic T, Pejsa V, Lucijanic J, Fazlic Dzankic A et al (2018) Elevated neutrophil-to-lymphocyte-ratio and platelet-to-lymphocyte ratio in myelofibrosis: inflammatory biomarkers or representatives of Myeloproliferation itself? Anticancer Res 38(5):3157\u20133163. https:\/\/doi.org\/10.21873\/anticanres.12579","journal-title":"Anticancer Res"},{"issue":"8","key":"6023_CR40","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.numecd.2022.04.013","volume":"32","author":"SS Kwon","year":"2022","unstructured":"Kwon SS, Yoon SY, Jeong SY, Lee MY, Kim KH, Lee N, Won JH (2022) Neutrophil-lymphocyte ratio and carotid plaque burden in patients with essential thrombocythemia and polycythemia vera. Nutr Metab Cardiovasc Dis 32(8):1913\u20131916. https:\/\/doi.org\/10.1016\/j.numecd.2022.04.013","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"2","key":"6023_CR41","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41408-022-00625-5","volume":"12","author":"A Carobbio","year":"2022","unstructured":"Carobbio A, Vannucchi AM, De Stefano V, Masciulli A, Guglielmelli P, Loscocco GG et al (2022) Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera. Blood Cancer J 12(2):28. https:\/\/doi.org\/10.1038\/s41408-022-00625-5","journal-title":"Blood Cancer J"},{"key":"6023_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.leukres.2018.03.013","volume":"69","author":"D Zhou","year":"2018","unstructured":"Zhou D, Chen W, Cheng H, Qiao JL, Zhu LL, Li ZY, Xu KL (2018) Clinico-hematological profile and thrombotic\/hemorrhagic events in 150 Chinese patients with essential thrombocythemia. Leuk Res 69:1\u20136. https:\/\/doi.org\/10.1016\/j.leukres.2018.03.013","journal-title":"Leuk Res"},{"issue":"7","key":"6023_CR43","first-page":"3036","volume":"28","author":"MZ Kocak","year":"2017","unstructured":"Kocak MZ, Da\u011fl\u0131 M, \u00dcnl\u00fc A (2017) The ratio of platelet\/lymphocyte, the ratio of neutrophil\/lymphocyte and some haemogram parameters related to thrombosis in essential thrombocytosis and polycythaemia vera. Biomed Res 28(7):3036\u20133039","journal-title":"Biomed Res"},{"issue":"13","key":"6023_CR44","doi-asserted-by":"publisher","first-page":"5159","DOI":"10.7314\/APJCP.2015.16.13.5159","volume":"16","author":"T Hacibekiroglu","year":"2015","unstructured":"Hacibekiroglu T, Akinci S, Basturk A, inal B, Guney T, Bakanay SM, Dilek I (2015) Evaluation of inflammation parameters in Philadelphia negative chronic myeloproliferative neoplasia patients. Asian Pac J Cancer Prev 16(13):5159\u20135162. https:\/\/doi.org\/10.7314\/APJCP.2015.16.13.5159","journal-title":"Asian Pac J Cancer Prev"},{"issue":"10","key":"6023_CR45","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.3390\/cancers12103061","volume":"12","author":"M Brabrand","year":"2020","unstructured":"Brabrand M, Frederiksen H (2020) Risks of solid and lymphoid malignancies in patients with myeloproliferative neoplasms: clinical implications. Cancers (Basel) 12(10):3061. https:\/\/doi.org\/10.3390\/cancers12103061","journal-title":"Cancers (Basel)"},{"issue":"9","key":"6023_CR46","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1182\/blood.2020008043","volume":"137","author":"AR Moliterno","year":"2021","unstructured":"Moliterno AR, Ginzburg YZ, Hoffman R (2021) Clinical insights into the origins of thrombosis in myeloproliferative neoplasms. Blood 137(9):1145\u20131153. https:\/\/doi.org\/10.1182\/blood.2020008043","journal-title":"Blood"},{"issue":"6","key":"6023_CR47","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.3390\/ijms23063177","volume":"23","author":"C Cumbo","year":"2022","unstructured":"Cumbo C, Anelli L, Zagaria A, Coccaro N, Tarantini F, Specchia G et al (2022) Second Cancer Onset in Myeloproliferative neoplasms: what, when, why? Int J Mol Sci 23(6):3177. https:\/\/doi.org\/10.3390\/ijms23063177","journal-title":"Int J Mol Sci"},{"issue":"5","key":"6023_CR48","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1182\/blood.2019002614","volume":"135","author":"V De Stefano","year":"2020","unstructured":"De Stefano V, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N et al (2020) Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. Blood 135(5):381\u2013386. https:\/\/doi.org\/10.1182\/blood.2019002614","journal-title":"Blood"},{"issue":"3","key":"6023_CR49","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3324\/haematol.2010.033506","volume":"96","author":"MG Della Porta","year":"2011","unstructured":"Della Porta MG, Malcovati L, Strupp C, Ambaglio I, Kuendgen A, Zipperer E et al (2011) Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 96(3):441\u2013449. https:\/\/doi.org\/10.3324\/haematol.2010.033506","journal-title":"Haematologica"},{"issue":"19","key":"6023_CR50","doi-asserted-by":"publisher","first-page":"4698","DOI":"10.3390\/cancers15194698","volume":"15","author":"KL Koster","year":"2023","unstructured":"Koster KL, Messerich NM, Volken T, Cogliatti S, Lehmann T, Graf L et al (2023) Prognostic significance of the myelodysplastic syndrome-specific Comorbidity Index (MDS-CI) in patients with myelofibrosis: a retrospective study. Cancers (Basel) 15(19):4698. https:\/\/doi.org\/10.3390\/cancers15194698","journal-title":"Cancers (Basel)"},{"issue":"2","key":"6023_CR51","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1365-2141.2006.06430.x","volume":"136","author":"M Di Nisio","year":"2007","unstructured":"Di Nisio M, Barbui T, Di Gennaro L, Borrelli G, Finazzi G, Landolfi R et al (2007) The haematocrit and platelet target in polycythemia vera. Br J Haematol 136(2):249\u2013259. https:\/\/doi.org\/10.1111\/j.1365-2141.2006.06430.x","journal-title":"Br J Haematol"},{"issue":"6","key":"6023_CR52","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","volume":"109","author":"A Carobbio","year":"2007","unstructured":"Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R et al (2007) Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 109(6):2310\u20132313. https:\/\/doi.org\/10.1182\/blood-2006-09-046342","journal-title":"Blood"},{"issue":"6","key":"6023_CR53","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","volume":"109","author":"R Landolfi","year":"2007","unstructured":"Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R et al (2007) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 109(6):2446\u20132452. https:\/\/doi.org\/10.1182\/blood-2006-08-042515","journal-title":"Blood"},{"issue":"12","key":"6023_CR54","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/ajh.27079","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A, Loscocco GG, Farrukh F, Szuber N, Mannelli F, Pardanani A et al (2023) A globally applicable triple A risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count. Am J Hematol 98(12):1829\u20131837. https:\/\/doi.org\/10.1002\/ajh.27079","journal-title":"Am J Hematol"},{"issue":"7","key":"6023_CR55","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1080\/09537104.2016.1224828","volume":"27","author":"P Noris","year":"2016","unstructured":"Noris P, Melazzini F, Balduini CL (2016) New roles for mean platelet volume measurement in the clinical practice? Platelets 27(7):607\u2013612. https:\/\/doi.org\/10.1080\/09537104.2016.1224828","journal-title":"Platelets"},{"issue":"5","key":"6023_CR56","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.exphem.2007.01.053","volume":"35","author":"A Falanga","year":"2007","unstructured":"Falanga A, Marchetti M, Vignoli A, Balducci D, Russo L, Guerini V, Barbui T (2007) V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol 35(5):702\u2013711. https:\/\/doi.org\/10.1016\/j.exphem.2007.01.053","journal-title":"Exp Hematol"},{"key":"6023_CR57","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","volume":"9","author":"A Kaifie","year":"2016","unstructured":"Kaifie A, Kirschner M, Wolf D, Maintz C, H\u00e4nel M, Gattermann N et al (2016) Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol 9:18. https:\/\/doi.org\/10.1186\/s13045-016-0242-9","journal-title":"J Hematol Oncol"},{"issue":"10","key":"6023_CR58","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.exphem.2009.07.005","volume":"37","author":"K Hussein","year":"2009","unstructured":"Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlu\u00e9 J et al (2009) JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp Hematol 37(10):1186\u20131193e7. https:\/\/doi.org\/10.1016\/j.exphem.2009.07.005","journal-title":"Exp Hematol"},{"issue":"16","key":"6023_CR59","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.3390\/cancers15164180","volume":"15","author":"D Lekovic","year":"2023","unstructured":"Lekovic D, Bogdanovic A, Sobas M, Arsenovic I, Smiljanic M, Ivanovic J et al (2023) Easily Applicable Predictive score for Differential diagnosis of Prefibrotic primary myelofibrosis from essential thrombocythemia. Cancers (Basel 15(16):4180. https:\/\/doi.org\/10.3390\/cancers15164180","journal-title":"Cancers (Basel"},{"issue":"9","key":"6023_CR60","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.6004\/jnccn.2022.0046","volume":"20","author":"AT Gerds","year":"2022","unstructured":"Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A et al (2022) Myeloproliferative neoplasms, Version 3.2022, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw 20(9):1033\u20131062. https:\/\/doi.org\/10.6004\/jnccn.2022.0046","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06023-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06023-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06023-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T20:05:47Z","timestamp":1730837147000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06023-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":60,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["6023"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06023-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"22 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approved by the Ethics Committee of the University Clinical Center of Serbia, Belgrade, Serbia, Nr: 499\/05 from 30.11.2021.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was waived because we had no contact with study patients and the data used for analyses did not contain any personal identifiers.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"N.A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}},{"value":"N.A.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}